Table 2. CTCs prevalence in recurrent/metastatic head and neck cancer patients.
Characteristic | n (%) | |
Evaluable patients | 53 (100) | |
CTCs+ pts at baseline | 14 (26) | |
CTCs numbers at baseline | Median CTCs | 1 |
Mean CTCs ± SD | 5±10 | |
Range | 1–43 | |
CTCs+ pts at anytime | 22 (41) | |
N. of CTCs determinations | 1 | 16 (31) |
2 | 21 (39) | |
3 | 5 (9) | |
4 | 11 (21) |